PATH | VRL
Menu

The Immunogenicity of Fractional Intradermal Doses of the Inactivated Poliovirus Vaccine is Associated With the Size of the Intradermal Fluid Bleb

In response to the global shortage of inactivated poliovirus vaccine (IPV), the World Health Organization now recommends the use of fractional (one-fifth) intradermal doses of IPV (ID fIPV), both in campaigns and routine immunization schedules. This article, published in Clinical Infectious Diseases, discusses the results of a study in The Gambia, which found the immunogenicity of ID fIPV to be significantly positively correlated with intradermal fluid bleb size. While previous studies reported consistently lower immunogenicity of ID fIPV compared with a full dose of the vaccine, this study found the difference could be largely overcome when a bleb size of 8 to 10 millimeters is generated. Based on their findings, the authors recommend a focus on maximizing the bleb size generated when training vaccinators to administer ID fIPV. Furthermore, the findings suggest the importance of next-generation device optimization based in bleb measurement, and may have broader implications for the future delivery of other vaccines by the intradermal route.

Author: Bibby J, Saidu Y, Umesi A, et al.

Published: 2017

» Visit web page (English)

(Located at academic.oup.com)

Citation: Bibby J, Saidu Y, Umesi A, et al. The Immunogenicity of Fractional Intradermal Doses of the Inactivated Poliovirus Vaccine is Associated With the Size of the Intradermal Fluid Bleb. Clinical Infectious Diseases. 2017;65(5):851-854.

Resource types: Peer-reviewed journal

Diseases/vaccines: Polio

Topics: Vaccine safety and performance, Disease/vaccine specific information, Delivery technologies

Regions: Africa